This Phase II/III multicenter double-blind, randomized, placebo- controlled, parallel study will evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of intravenous aptiganel hydrochloride versus placebo in patients with acute ischemic stroke.
Showing the most recent 10 out of 642 publications